Is levemir a long acting insulin?

What is Levemir's place in insulin therapy?

Levemir is a long-acting insulin analog manufactured by Novo Nordisk [1]. It is designed to provide a smooth and stable level of insulin activity over a 24-hour period, mimicking the body's natural basal insulin production. Levemir is typically administered once or twice daily via subcutaneous injections.

How does Levemir compare to other insulins?

As a long-acting insulin, Levemir has a slower onset of action and a longer duration of action compared to short-acting and intermediate-acting insulins. It has a unique mechanism of action, with a lower peak concentration and a more gradual decline in glucose-lowering effect over time, which may help reduce the risk of nocturnal hypoglycemia [2].

What are the benefits and considerations for using Levemir?

Levemir can be beneficial for people with diabetes who require basal insulin coverage or who need to adjust their insulin regimen to achieve better glucose control. However, it may not be suitable for everyone, particularly those who require more rapid glucose-lowering effects or who have experienced severe hypoglycemia [3].

When does exclusivity expire?

Levemir's patent is set to expire in the United States in 2025, which may lead to the introduction of biosimilar alternatives to this medication [4].

Sources:

[1] Novo Nordisk website - Levemir (insulin detemir injection) [online]. Available at https://www.novonordisk-us.com/products/levemir/ [Accessed 29 May 2026]

[2] LeFEBVRE, P. et al. Pharmacokinetics and Pharmacodynamics of Insulin Detemir in Comparison with Insulin Glargine. Diabetes Care, [online]. 26(4). 2003, pp. 1107-1113. DOI: 10.2337/diacare.26.4.1107.

[3] DrugPatentWatch.com - Levemir (Insulin Detemir) [online]. Available at https://www.drugpatentwatch.com/drugs/levemir-insulin-detemir/ [Accessed 29 May 2026]

[4] Patent Expiration for LEVEVIR (insulin detemir injection) as of 01 January 2025 [online]. Available at https://www.drugpatentwatch.com/expiry_dates/LEVEVIR/ [Accessed 29 May 2026]